Priority 12 from the Myeloma (Canada) PSP
| UNCERTAINTY: What genes are associated with the development of myeloma, and how can genetic testing be incorporated into the diagnosis and treatment of myeloma? (JLA PSP Priority 12) | |
|---|---|
| Overall ranking | 12 |
| JLA question ID | 0113/12 |
| Explanatory note | Participants wondered whether myeloma is genetic and, if so, what genes are implicated in its development. Furthermore, participants wanted to see increased use of genetic testing in the diagnosis and treatment of myeloma. Specifically, they asked about the use of genetic testing to predict the onset of myeloma, the role of genetics in the diagnosis of myeloma, treatments based on genetics, and the effects of genetics on treatment response and prognosis. |
| Evidence |
No evidence identified |
| Health Research Classification System category | Cancer and neoplasms |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | What are the underlying genetic links which may lead to a propensity to develop myeloma? ~ How many different genetic mutations have been identified? ~ Is there a genetic component to MM? * Are there any genetic anomalies that are the root cause of the myeloma mutation? ~ Is there a genetic connection to multiple myeloma? ~ Genetic information on the various forms of Myeloma treatments based on genetics ~ Linking treatment to genetic information on the disease |
| Submitted by | Please see the PSP Engagement Summary on the JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0113 |
| PSP name | Myeloma (Canada) |
| Total number of uncertainties identified by this PSP. | 59 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 28 April 2021 |